OSCR
Oscar Health, Inc.
OSCR has the edge over QCOM overall, supported by stronger fundamentals and stronger modeled upside.
QCOM
QUALCOMM Incorporated
QCOM offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
QCOM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
QCOM's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over QCOM in the historical PE scenario, which offers more potential upside but is not a forecast.
QCOM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $175 | -1.1% |
| Current | 14x | $177 | — |
| Fair | 20x | $248 | +40% |
| Expensive | 26x | $333 | +88% |
Historical ranges are pointers, not guarantees.
QCOM's PE is in its cheap range at 14x.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
QCOM Forward outlook
There aren't enough analyst estimates for QCOM to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
QCOM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $12.70 | +153% |
| Q2 2026 | $8.76 | -15% |
| Q1 2026 | $9.32 | -4.9% |
| Q4 2025 | $4.96 | -47% |
| Q3 2025 | $5.01 | -44% |
| Q2 2025 | $10.35 | +34% |
| Q1 2025 | $9.80 | +32% |
| Q4 2024 | $9.34 | +35% |
QCOM earned $12.70 per share over the past year, up 153% from the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over QCOM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
QCOM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.3B | -8.4% |
| Q2 2026 | $9.9B | -4% |
| Q1 2026 | $10.6B | -3.5% |
| Q4 2025 | $12.3B | +5% |
| Q3 2025 | $11.3B | +10% |
| Q2 2025 | $10.4B | +10% |
| Q1 2025 | $11B | +17% |
| Q4 2024 | $11.7B | +17% |
QCOM's revenue grew through 2024 and has held roughly level since: $10.3B last quarter, down 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -13 points |
| Q2 2026 | 16% | -10 points |
| Q1 2026 | 22% | -6.6 points |
| Q4 2025 | 27% | -3 points |
| Q3 2025 | 26% | +0.7 points |
| Q2 2025 | 27% | +3 points |
| Q1 2025 | 28% | +3.5 points |
| Q4 2024 | 30% | +1 points |
QCOM has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over QCOM on cash flow, with more consistent year-over-year improvement.
QCOM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.8B | -49% |
| Q2 2026 | $495M | -81% |
| Q1 2026 | $1.9B | -18% |
| Q4 2025 | $4.4B | +2.5% |
| Q3 2025 | $3.6B | +50% |
| Q2 2025 | $2.6B | -3.2% |
| Q1 2025 | $2.3B | -31% |
| Q4 2024 | $4.3B | +58% |
QCOM's free cash flow has been positive every quarter for seven years: $8.7B over the past year, down 33% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
QCOM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +4M shares |
| 1 year | -2.9% | -32M shares |
| 3 years | -4.7% | -53M shares |
| 5 years | -6.6% | -76M shares |
| Available history | -7.4% | -86M shares |
QCOM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1B |
| Q2 2026 | $1.4B |
| Q1 2026 | $2.8B |
| Q4 2025 | $2.7B |
| Q3 2025 | $2.4B |
| Q2 2025 | $2.8B |
| Q1 2025 | $1.7B |
| Q4 2024 | $1.8B |
QCOM spent $7.8B buying back its own shares over the past year, down 11% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over QCOM on leverage, with a lower net debt burden relative to earnings.
QCOM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.0x | Healthy |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
QCOM's net debt is about a year of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
QCOM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 40.2 | Neutral |
QCOM's weekly RSI is 51 (neutral) and its Stochastic is 40 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over QCOM on valuation relative to its sector.
QCOM PE vs Technology Sector
| Metric | QCOM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 28x | 50% below |
| PE % | 17 | 35 | 18 pts below |
QCOM is trading at 14x earnings, a 50% discount to the Technology sector's median of 28x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over QCOM on trend strength, trading above more of its moving averages.
QCOM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $177.2 | 0% below |
| 20 week MA | $172.8 | 2.5% above |
| 50 week MA | $170.7 | 3.8% above |
| 100 week MA | $164.3 | 7.8% above |
| 200 week MA | $155.1 | 14% above |
QCOM's trend is up, with a small recent dip: it's below only its 8-week average, and 14% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over QCOM on returns for 2026, with the stronger performance.
QCOM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.8 | $148.8 | +68% |
| 2021 | $148.8 | $182.7 | +23% |
| 2022 | $182.7 | $110.8 | -39% |
| 2023 | $110.8 | $144.6 | +30% |
| 2024 | $144.6 | $157.2 | +8.7% |
| 2025 | $157.2 | $174.8 | +11% |
| 2026 YTD | $174.8 | $177.1 | +1.3% |
QCOM has finished higher in five of the last six years. It's up 1.3% so far in 2026.